AB InBev Declines Comment on Industry Concerns Regarding GLP-1 Weight-Loss Drugs

Anheuser-Busch InBev has chosen not to comment on industry concerns regarding the potential impact of GLP-1 weight-loss medications on alcohol consumption. Competitors like Heineken are adapting by promoting low- and no-alcohol options in response to changing consumer preferences. While some industry stakeholders are addressing these trends, others argue that current data does not conclusively connect these medications to changes in beer consumption patterns.